Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1)

Moradian, Siamak; Faghihi, Hooshang; Sadeghi, Babak; Piri, Niloofar; Ahmadieh, Hamid; Soheilian, Masoud; Dehghan, Mohammad Hossein; Azarmina, Mohsen; Esfahani, Mohammad Riazi

doi:10.1007/s00417-010-1440-8

Cited by 29 publications

(30 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that VEGF is a key factor for macular edema in retinal vein occlusion [20,21], Therefore, inhibition of VEGF should theoretically offer a therapeutic benefit for BRVO. This effect has been shown with anti-VEGF drugs such as bevacizumab [8][9][10][11][12][22][23][24], ranibizumab [25,26], and pegaptanib [27] in terms of both VA improvement and CMT reduction. However, there are some concerns about their safety and their adverse effect on macular perfusion.…”

Section: Discussionmentioning

confidence: 91%

“…Instead of the usual dosage of IVT (4 mg) [39,40], we administered 2 mg in order to reduce the side-effects of the drug. Most studies demonstrated a temporary beneficial effect of both IVB [20,22,41] and IVT [20,31,37,41] [31]. Because of these reported recurrences after intravitreal injections, we planned a prescheduled repeated therapy for both drugs.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion

Ramezani

Esfandiari

Entezari

et al. 2012

Graefes Arch Clin Exp Ophthalmol

Self Cite

View full text Add to dashboard Cite

Both 3-times-monthly IVB injections and 2-times IVT injections with a 2-month interval could be effective for improving BCVA and CMT in cases with recent-onset BRVO up to 6 months. However, considering the better visual and anatomic outcomes after IVB injections and the potential complications of IVT injections, we would recommend prescheduled repeated IVB injections for such cases. The favorable responses were more pronounced in the ischemic types of BRVO in this trial; nevertheless, this should be confirmed in larger studies.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 97%

Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion

Ramezani

Esfandiari

Entezari

et al. 2012

Graefes Arch Clin Exp Ophthalmol

Self Cite

View full text Add to dashboard Cite

show abstract

“…BRVO usually occurs at an arteriovenous crossing and the degree of macular involvement determines the level of visual impairment, which may result from ischemic damage and/or secondary macular edema. Macular edema is common in eyes affected by BRVO (5-15 % in 1 year), and represents the most common cause of vision loss in these patients [4,5]. Treatment modalities for BRVO-associated macular edema have been mainly limited to retinal laser photocoagulation (grid pattern and sector scatter) and/or intravitreal corticosteroids for the past few years [6].…”

Section: Introductionmentioning

confidence: 99%

Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review

Yilmaz

Cordero‐Coma

2012

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Clinicians should use this review as an indicator that IVB is effective in improving VA and CMT values in the long-term in patients with BRVO-associated macular edema. It is important to note, however, that statistically significant improvements in VA in the short term could be seen. This review's main aim was to serve as an evidence base for potentially using other modalities, such as IVB, which seems to be reserved for certain cases.

show abstract

“…Early-phase CTs (phases I/II and III) showed a significant increase over time in the use of biomarkers for patient selection and stratification (including predictive, diagnostic Although 30 of 59 (50.8%) of phase III CTs used secondary surrogate imaging endpoints, we found only 3 of 59 (5.1%) phase III CTs including primary surrogate imaging endpoints: two on retina 16,17 (macular thickness by optical coherence tomography [OCT] and lesion enlargement by fundus autofluorescence) and one on glaucoma 18 (iris color photography). Conversely, phase IV CTs included primary surrogate imaging endpoints in 75 of 275 (27.2%) cases; P < 0.001.…”

Section: Thementioning

confidence: 50%

Decade-Long Profile of Imaging Biomarker Use in Ophthalmic Clinical Trials

Massaro

Scaramuzzi

Hamrah

et al. 2017

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE. The purpose of this study was to investigate the use of imaging biomarkers in published clinical trials (CTs) in ophthalmology and its eventual changes during the past 10 years. METHODS.We sampled from published CTs in the fields of cornea, retina, and glaucoma between 2005-2006 and 2015-2016. Data collected included year of publication, phase, subspecialty, location, compliance with Consolidated Standards for Reporting Trials, impact factor, presence and use of imaging biomarkers (diagnostic, prognostic and predictive; primary and secondary surrogate endpoints), and use of centralized reading centers.RESULTS. We included 652 articles for analysis, equally distributed in three timeframes (2005-2006, 2010-2011, and 2015-2016), mainly reporting phase IV CTs and trials on procedures (42.2% and 35.4%, respectively). Imaging biomarkers were included in 46.3% of the analyzed CTs and their use significantly increased over time (P < 0.05). Optical coherence tomography was the most frequently used device (27.7%), whereas diagnostic biomarkers and secondary surrogate endpoints were the most frequent biomarker types (19.5% and 22.5%, respectively). Early-phase CTs showed an increase in the use of biomarkers for patient selection and stratification over time (P < 0.05), but not in the use of imaging surrogate endpoints (P ¼ 0.90). Only 3 of 59 (5.1%) of phase III CTs included primary surrogate imaging endpoints, whereas secondary surrogate imaging endpoints were present in 50.8% of these trials (P < 0.001). Retinal CTs had the highest prevalence for each type of imaging biomarker (P < 0.001). Reading centers were used in 52 of 302 CTs (17.2%), with no significant time-related increase.CONCLUSIONS. Imaging biomarkers are increasingly used in published CTs in ophthalmology. Additional efforts, including centralized reading centers, are needed to improve their validation and use, allowing a wider use of these tools as primary surrogate endpoints in phase III CTs.

show abstract

Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1)

Cited by 29 publications

References 35 publications

Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion

Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent-onset branch retinal vein occlusion

Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review

Decade-Long Profile of Imaging Biomarker Use in Ophthalmic Clinical Trials

Contact Info

Product

Resources

About